Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

By Argiris Athanassios  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1575-1584

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab/cetuximab: Hypertension and skin toxicity: case report

By  

Reactions Weekly, Vol. 1, Iss. 1273, 2009-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

By Dent S.   Gelmon K.   Chi K.   Jonker D.   Wainman N.   Capier C.   Chen E.   Lyons J.   Seymour L.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1522-1529

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

By Burris Howard   Jones Suzanne   Williams Daphne   Kathman Steven   Hodge Jeffrey   Pandite Lini   Ho Peter   Boerner Scott   LoRusso Patricia  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 467-472

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 71-84

Bentham Science Publishers

Access to resources Recommend Favorite